Health ❯ Healthcare ❯ Patient Outcomes

Weight Loss

Clinical Efficacy A1C Reduction Factors Influencing Treatment Success Long-term Health Benefits Glycemic Control Orforglipron SURMOUNT-1 Trial Skin Clearance Pain Management Disease Remission Body Weight Reduction Long-term Effects Sustained Weight Loss Health Markers Side Effects Physical Function Improvement

Meta-Analysis Finds Tirzepatide Produces Largest Average Weight Loss Among FDA‑Approved GLP‑1s

Linked to dual GLP‑1/GIP targeting, tirzepatide showed larger average weight loss in trials with uncertain post‑treatment durability.

New Analyses Find Weight-Loss Surgery Outperforms GLP-1 Drugs as Prescriptions Soar

Lilly’s Taltz Plus Zepbound Outperforms Taltz Alone in Phase 3b Psoriasis-Obesity Trial

Amgen Advances Monthly Obesity Drug to Phase 3 After 20% Weight Loss in Mid-Stage Trial

Real-World GLP-1 Therapy Yields Lower Weight Loss, Spurs Tetra-Receptor Drug Research